Complexities of Pain Management
Our understanding of pain and its underlying mechanisms is still evolving, and pain management for patients has relied heavily on the use of anti-inflammatories, opioids and other analgesics, all of which pose significant risk of complications.
Bioactive acyl ethanolamides, such as palmitoylethanolamide (PEA), are produced naturally in the body as part of a biological repair mechanism and serve as effective modulators of inflammation and chronic and/or nerve pain in the human body. The mechanisms are multi-faceted and include neuroprotective and anti-inflammatory capabilities, as well as lipid modulating effects. We are now just understanding the significance of the role these molecules play in pain and inflammation, the analgesic properties of PEA and how to use supplemental PEA as a therapy for treatment of chronic pain and neuro-inflammation.
Arguably regarded as the leading Australian expert on PEA, Dr Elizabeth Steels has been conducting clinical trials on PEA, as well as prescribing PEA in clinic for over 6 years. She will also share her insights into the history of ALIAmides, the pharmacokinetics of PEA and the use of PEA for chronic pain conditions.
By participating in this webinar you will:
· Gain a thorough understanding of the ALIAmide theory of pain control and the physiological roles of bioactive acyl ethanolamides in health and neuro-inflammation
· Fully comprehend the role of PEA in intracellular signalling mechanisms and its metabolic pathways of synthesis and degradation
· Consider the specific recommendations around PEA dosing and timing to optimise bioavailability and maintain serum levels for peak therapeutic benefits
· Review the clinical evidence for the use of PEA in management of acute and chronic pain
· Learn how to confidently prescribe PEA effectively for management of chronic pain and inflammatory conditions
Materials available include:
- Video Recordings
- Audio Recordings
- Digital Notes and Resources
- CPE Certificate of Attendance (1.5 Contact Hours)